SEGMENT INFORMATION (Tables)

3 Months Ended

Dec. 31, 2022

SEGMENT INFORMATION

Schedule of information regarding operations by segment

Information regarding operations by segment for the three-month period ended December 31, 2022 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services		Security Products		Consolidated
Revenues:
Product revenues	$	127,506	$	—	$	388,890	$	516,396
Service revenues		121,743		—		110,318		232,061
Clinical laboratory service revenues		—		4,565,815		—		4,565,815
Less intersegment revenues		—		(51,520)		—		(51,520)
Total revenues	$	249,249	$	4,514,295	$	499,208	$	5,262,752
Gross profit	$	170,924	$	1,933,219	$	273,540	$	2,377,683
(Loss) income from segment operations (a)	$	(852,253)	$	1,109,884	$	(474,715)	$	(217,084)

Information regarding operations by segment for the three-month period ended December 31, 2021 is as follows:

	Therapeutic DNA		MDx Testing		DNA Tagging and
	Production		Services		Security Products		Consolidated
Revenues:
Product revenues	$	—	$	342,821	$	483,490	$	826,311
Service revenues		89,438		—		49,835		139,273
Clinical laboratory service revenues		—		3,349,658		—		3,349,658
Less intersegment revenues		—		(149,536)		—		(149,536)
Total revenues	$	89,438	$	3,542,943	$	533,325	$	4,165,706
Gross profit	$	89,438	$	820,690	$	199,010	$	1,109,138
(Loss) income from segment operations (a)	$	(924,778)	$	(334,988)	$	(896,399)	$	(2,156,165)

(a) Segment operating loss consists of net sales, less cost of sales, specifically identifiable research and development, and selling, general and administrative expenses.

Schedule of reconciliation of segment loss from operations to corporate loss

	December 31,
	2022		2021
Loss from operations of reportable segements	$	(217,084)	$	(2,156,165)
General corporate expenses (b)		(1,001,894)		(2,550,412)
Interest income, net		3,686		273
Unrealized loss on change in fair value of warrants classified as a liability		(2,637,800)		—
Other income (expense), net		8,846		(14,607)
Consolidated loss before provision for income taxes	$	(3,844,246)	$	(4,720,911)

(b) General corporate expenses consists of Selling, general and administrative expenses that are not specifically identifiable to a segment.